Literature DB >> 21741159

Current pathology keys of renal cell carcinoma.

Ferran Algaba1, Hideyuki Akaza, Antonio López-Beltrán, Guido Martignoni, Holger Moch, Rodolfo Montironi, Victor Reuter.   

Abstract

CONTEXT: Renal cell carcinoma (RCC) in adults comprises a heterogeneous group of tumours with variable clinical outcomes that range from indolent to overtly malignant. The application of molecular genetic techniques to the study of renal neoplasms has resulted in an improved classification of these entities and a better understanding of the biologic mechanisms responsible for tumour development and progression. The current 2004 World Health Organisation classification of adult renal epithelial neoplasms has expanded rapidly with new categories recently incorporated.
OBJECTIVE: To review and evaluate the evidence implicating pathologic features and classification of RCC in adults as a tool to approach patients' prognosis and modulate current therapy. EVIDENCE ACQUISITION: Members of Committee 3: Pathology, under the auspices of the International Consultation on Urological Diseases and the European Association of Urology (ICUD-EAU) International Consultation on Kidney Cancer, performed a systematic review using PubMed. Participating pathologists discussed pathologic categories and diagnostic features of RCC in adults. EVIDENCE SYNTHESIS: We reviewed and discussed articles and the personal experiences of participating uropathologists.
CONCLUSIONS: The conclusions reached by the ICUD-EAU 2010 International Consultation on Kidney Cancer emphasise the appropriate pathologic diagnosis of RCC in adults as a tool to approach patients' prognosis and modulate current therapy. Further emphasis should be placed on defining risk groups of RCC and diagnostic features of unusual tumours such as familial RCC, translocation RCC, and tubular mucinous and spindle cell carcinoma. A number of recently described entities and morphologic variants of classical categories deserves recognition because they can be important in differential diagnosis and therapy.
Copyright © 2011 Ferran Algaba. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21741159     DOI: 10.1016/j.eururo.2011.06.047

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  28 in total

1.  Genetic architecture of renal cell carcinoma: Do we have to know?

Authors:  Hakan Öztürk
Journal:  World J Urol       Date:  2015-09-28       Impact factor: 4.226

Review 2.  The Effect of Targeted Therapy for Genitourinary Malignancies on Sexual Function and Fertility.

Authors:  Bradley C Holland; Zubin Shetty; Shaheen Alanee
Journal:  Curr Urol Rep       Date:  2017-08       Impact factor: 3.092

Review 3.  Management of Atypical Renal Cell Carcinomas.

Authors:  Bobby C Liaw; Reza Mehrazin; Charles Baker; John P Sfakianos; Che-Kai Tsao
Journal:  Curr Treat Options Oncol       Date:  2017-09-14

Review 4.  Renal cell carcinoma.

Authors:  James J Hsieh; Mark P Purdue; Sabina Signoretti; Charles Swanton; Laurence Albiges; Manuela Schmidinger; Daniel Y Heng; James Larkin; Vincenzo Ficarra
Journal:  Nat Rev Dis Primers       Date:  2017-03-09       Impact factor: 52.329

Review 5.  [Renal cancer biomarkers. What is justified?].

Authors:  H Moch
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

6.  Unlike in clear cell renal cell carcinoma, KRAS is not mutated in multilocular cystic clear cell renal cell neoplasm of low potential.

Authors:  Maria Rosaria Raspollini; Francesca Castiglione; Guido Martignoni; Liang Cheng; Rodolfo Montironi; Antonio Lopez-Beltran
Journal:  Virchows Arch       Date:  2015-10-05       Impact factor: 4.064

7.  Comparative study of CT appearances in mucinous tubular and spindle cell carcinoma and collecting duct carcinoma of the kidney.

Authors:  Jingtao Wu; Qingqiang Zhu; Wenrong Zhu; Wenxin Chen; Shouan Wang
Journal:  Br J Radiol       Date:  2015-10-05       Impact factor: 3.039

8.  IRF1 suppresses Ki-67 promoter activity through interfering with Sp1 activation.

Authors:  Feifei Chen; Jian Song; Jiehui Di; Qing Zhang; Hui Tian; Junnian Zheng
Journal:  Tumour Biol       Date:  2012-08-14

Review 9.  Biomarkers in renal cancer.

Authors:  Holger Moch; John Srigley; Brett Delahunt; Rodolfo Montironi; Lars Egevad; Puay Hoon Tan
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

10.  Extensive peritoneal carcinomatosis secondary to renal cell carcinoma with sarcomatoid and rhabdoid differentiation.

Authors:  Ashwini K Esnakula; Tammey J Naab; William Green; Babak Shokrani
Journal:  BMJ Case Rep       Date:  2013-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.